Organogenesis Holdings Announces Publication Of Results From PREPARE, Multicenter, RCT Evaluating PuraPlyAM Plus SoC Compared To SoC Alone In Hard-To-Heal Diabetic Foot Ulcers
Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the publication of
Organogenesis published study results showing their wound care product works well. When a company proves their medicine actually helps patients, that builds trust in the business.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.